Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer

BACKGROUND: Adjuvant gemcitabine for pancreatic cancer has limited efficacy in the clinical setting. Impaired drug metabolism is associated with treatment resistance. We aimed to evaluate the chemosensitising effect of interferon-beta (IFN-β). METHODS: BxPC-3, CFPAC-1, and Panc-1 cells were pre-trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Blaauboer, Amber, Booy, Stephanie, van Koetsveld, Peter M., Karels, Bas, Dogan, Fadime, van Zwienen, Suzanne, van Eijck, Casper H. J., Hofland, Leo J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7513525/
https://www.ncbi.nlm.nih.gov/pubmed/32967656
http://dx.doi.org/10.1186/s12885-020-07420-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7513525/
https://www.ncbi.nlm.nih.gov/pubmed/32967656
http://dx.doi.org/10.1186/s12885-020-07420-0

Ejemplares similares